Medidata Solutions (NASDAQ:MDSO) was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating in a report released on Wednesday, The Fly reports.
A number of other equities research analysts have also recently weighed in on MDSO. Guggenheim cut shares of Medidata Solutions from a “buy” rating to a “neutral” rating in a research note on Wednesday. Zacks Investment Research cut shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. BidaskClub upgraded shares of Medidata Solutions from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 20th. Dougherty & Co cut shares of Medidata Solutions from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 1st. Finally, Wells Fargo & Co cut shares of Medidata Solutions from an “outperform” rating to a “market perform” rating and set a $90.00 price objective on the stock. in a research note on Tuesday, April 23rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $84.23.
Shares of NASDAQ MDSO opened at $94.75 on Wednesday. Medidata Solutions has a fifty-two week low of $60.10 and a fifty-two week high of $98.60. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.29. The stock has a market cap of $5.90 billion, a P/E ratio of 98.70, a P/E/G ratio of 8.43 and a beta of 1.31.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.33. Medidata Solutions had a net margin of 7.99% and a return on equity of 9.28%. The business had revenue of $173.50 million for the quarter, compared to analysts’ expectations of $172.12 million. During the same period in the previous year, the business earned $0.40 earnings per share. The company’s revenue was up 16.3% on a year-over-year basis. As a group, analysts predict that Medidata Solutions will post 0.79 earnings per share for the current fiscal year.
In related news, Director Robert Taylor sold 3,294 shares of Medidata Solutions stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $90.88, for a total transaction of $299,358.72. Following the transaction, the director now directly owns 41,757 shares of the company’s stock, valued at $3,794,876.16. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.70% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in MDSO. Quadrant Capital Group LLC increased its stake in Medidata Solutions by 126.8% in the 1st quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock worth $40,000 after purchasing an additional 331 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in Medidata Solutions by 127.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 945 shares of the company’s stock worth $64,000 after purchasing an additional 529 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in Medidata Solutions by 26.9% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,286 shares of the company’s stock worth $87,000 after purchasing an additional 273 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new position in Medidata Solutions in the 4th quarter worth about $90,000. Finally, Canton Hathaway LLC purchased a new position in Medidata Solutions in the 1st quarter worth about $109,000.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Recommended Story: NASDAQ Stock Market Explained
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.